Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Takeda Bags Global Rights to Protagonist’s Rare Hematology Asset
Takeda Pharmaceutical has snagged the global rights to develop and commercialize rusfertide, a late-stage asset of Protagonist Therapeutics being developed for rare chronic blood disorders. The companies struck a worldwide licensing and collaboration deal on January 31. Rusfertide is an…
To read the full story
Related Article
- US FDA Accepts Takeda’s Rusfertide Filing, Grants Priority Review
March 3, 2026
- Takeda Files Polycythemia Vera Drug Rusfertide in US
January 7, 2026
- Protagonist/Takeda’s Hematology Med Makes Mark in PIII
March 5, 2025
BUSINESS
- ASKA Inks AI Target Discovery Pact with Insilico in Women’s Health
March 25, 2026
- Shionogi to Fully Acquire Sleep Disorder JV SASS
March 25, 2026
- Stella Pharma Files Steboronine for Angiosarcoma
March 25, 2026
- Kyorin Bags Global Rights to UBE’s Early-Stage Asset
March 25, 2026
- Tremfya SC Induction Seen Cutting Hospital Time in UC: Expert
March 24, 2026
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…